BioSpace News Archive

Biotech Bay

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Olema Pharmaceuticals, Inc. announced that Molecular Cancer Therapeutics, an American Association for Cancer Research journal, has selected as a featured article a data publication that describes the distinct properties of palazestrant.

March 6, 2024
·
5 min read
Business

iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

iTeos Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

March 6, 2024
·
11 min read
Business

Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability

Kamada Ltd. announced financial results for the three months and year ended December 31, 2023.

March 6, 2024
·
21 min read
Business

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

ASLAN Pharmaceuticals Ltd. announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease that provides further support for the potential of eblasakimab as a biologic therapy for COPD.

March 6, 2024
·
9 min read
Business

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.

March 6, 2024
·
6 min read
Business

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

Applied Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

March 6, 2024
·
14 min read
Genetown

Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis

Sionna Therapeutics announced the closing of a $182 million Series C financing to support the clinical development of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator protein by stabilizing the first nucleotide-binding domain.

March 6, 2024
·
4 min read
Genetown

Tango Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Tango Therapeutics, Inc. announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in March.

March 6, 2024
·
1 min read
Policy

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Creative Medical Technology Holdings, Inc. is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration for CELZ-101, ImmCelzTM.

March 6, 2024
·
4 min read
BioMidwest

C₂N Diagnostics, LLC Announces Investment From Eisai Inc.

C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

March 6, 2024
·
3 min read